Sophie Andrieu-Key

  • Citations Per Year
Learn More
1. Oldenburg J, Cullen M, Tandstad T. Primum non nocere: do we harm stage I testicular cancer patients less by applying adjuvant chemotherapy than by failing to present this option? Ann Oncol 2015; 26: 255–256. 2. Vidal AD, Thalmann GN, Karamitopoulou-Diamantis E, Fey MF, Studer UE. Longterm outcome of patients with clinical stage I high-risk(More)
ALK-rearrangements are mainly encountered in lung adenocarcinomas and allow treating patients with anti-ALK targeted therapy. ALK-rearranged squamous cell lung carcinomas are rare tumors that can also respond to anti-ALK-targeted therapy. Nevertheless, ALK screening is not always performed in patients with squamous cell lung carcinomas making the(More)
Searching for ALK rearrangements has now become mandatory for the treatment of patients with advanced non-small cell lung cancer with anti-ALK-targeted therapy. The fluorescence in situ hybridization test is considered the "gold standard" to diagnose ALK-rearranged tumors. Nevertheless, some technical pitfalls may cause false-positive signals mimicking ALK(More)
Searching for ALK rearrangements using the approved fluorescent in situ hybridization (FISH) test and complementary immunohistochemistry (IHC) has become the rule to treat patients with advanced non‑small cell lung cancer (NSCLC) with anti‑ALK targeted therapy. The concordance between the two techniques is reported to be strong but imperfect. We report our(More)
CGS: cutaneous granulocytic sarcoma GS: granulocytic sarcoma IHC: immunohistochemistry KP: Koebner phenomenon MDS: myelodysplastic syndrome MPO: myeloperoxidase PG: pyoderma gangrenosum TGF-b1: transforming growth factor-beta 1 TGF-b1R: transforming growth factor-beta 1 receptor INTRODUCTION Granulocytic sarcoma (GS) is also known as myeloid sarcoma or(More)
  • 1